We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition
Read MoreHide Full Article
Intellia Therapeutics (NTLA - Free Report) has been focused on developing curative therapeutics using the CRISPR/Cas9 technology.
Please note that CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, is a technology that can selectively delete, modify or correct a disease-causing abnormality in a specific DNA segment. Although there are several methods to use CRISPR for targeting genetic defects that cause specific diseases, the most promising is the use of an enzyme called Cas9 for delivering CRISPR to the affected cells.
Intellia is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs wherein CRISPR is the therapy and ex vivo programs that use CRISPR to create the therapy.
Intellia is evaluating its leading in-vivo genome-editing candidate, NTLA-2001, in a phase I study for transthyretin amyloidosis with polyneuropathy. Per Intellia, NTLA-2001 offers the possibility to halt and even reverse the indication by reducing the transthyretin protein with a single-dose treatment.
Shares of Intellia have skyrocketed 122.9% so far this year against the industry’s 20.2% decline.
Image Source: Zacks Investment Research
While Intellia is yet to have an approved marketable product in its pipeline, the company’s collaboration deals help it access capabilities and resources to support the ongoing therapeutic programs.
Earlier in 2016, both Intellia and Regeneron Pharmaceuticals (REGN - Free Report) initially entered into a partnership to co-develop and commercialize CRISPR/Cas-based therapies, primarily focused on genome editing in the liver. In fact, NTLA-2001 is part of a co-development and co-promotion agreement with Regeneron. While Intellia is the lead party for NTLA-2001, Regeneron will share 25% of the development costs and commercial profits.
In 2020, the collaboration between the two companies was further expanded to co-develop therapies for hemophilia A and hemophilia B, with Regeneron being the lead party.
Intellia’s collaboration with Regeneron has been encouraging. As of Sep 30, 2021, the company recorded $145.0 million in upfront payments under the collaboration.
In October 2021, Intellia partnered with SparingVision to develop novel genomic medicines utilizing the CRISPR/Cas9 technology for the treatment of ocular diseases. SparingVision will fund the preclinical and clinical development for genome editing product candidates under the collaboration. Intellia will receive a 10% equity ownership stake in SparingVision and milestone payments up to $200 million per product.
Apart from NTLA-2001, the company is evaluating another in-vivo CRISP/Cas9 candidate in hereditary angioedema (HAE). Earlier this month, Intellia initiated a phase I/II study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-2002 in adults with type I or type II HAE.
Following the initiation of the phase I/II study, NTLA-2002 became the first single-dose CRISPR/Cas9 therapy designed to prevent attacks in HAE patients to enter clinical studies. NTLA-2002 aims to prevent HAE attacks by suppressing the plasma kallikrein activity. A reduction in kallikrein activity has been clinically validated in preventing HAE attacks.
NTLA-5001 is the company’s first wholly-owned ex-vivo genome editing candidate for the treatment of cancer. Intellia intends to start clinical studies for NTLA-5001 in acute myeloidleukemia.
A handful of other companies are also evaluating and/or developing their own in-vivo and ex-vivo therapies related to Intellia’s research and development programs.
One such company is CRISPR Therapeutics (CRSP - Free Report) , which is also developing therapies using the CRISPR/Cas9 technology.
CRISPR Therapeutics is evaluating its lead candidate, CTX001, in a phase I/II study for treating transfusion-dependent beta thalassemia and sickle cell disease. It expects regulatory submission for the therapy with the FDA in both indications by 2022-end.
Apart from CTX001, CRISPR Therapeutics is also pursuing the development of CRISPR candidates to create next generation CAR-T cell therapies.
Precision BioSciences’ loss per share estimates for 2021 have narrowed from $1.17 to $0.65 in the past 60 days. The same for 2022 has narrowed from $2.39 to $1.91 in the past 60 days.
Earnings of Precision BioSciences beat estimates in all the last four quarters, delivering a surprise of 76.9%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition
Intellia Therapeutics (NTLA - Free Report) has been focused on developing curative therapeutics using the CRISPR/Cas9 technology.
Please note that CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, is a technology that can selectively delete, modify or correct a disease-causing abnormality in a specific DNA segment. Although there are several methods to use CRISPR for targeting genetic defects that cause specific diseases, the most promising is the use of an enzyme called Cas9 for delivering CRISPR to the affected cells.
Intellia is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs wherein CRISPR is the therapy and ex vivo programs that use CRISPR to create the therapy.
Intellia is evaluating its leading in-vivo genome-editing candidate, NTLA-2001, in a phase I study for transthyretin amyloidosis with polyneuropathy. Per Intellia, NTLA-2001 offers the possibility to halt and even reverse the indication by reducing the transthyretin protein with a single-dose treatment.
Shares of Intellia have skyrocketed 122.9% so far this year against the industry’s 20.2% decline.
While Intellia is yet to have an approved marketable product in its pipeline, the company’s collaboration deals help it access capabilities and resources to support the ongoing therapeutic programs.
Earlier in 2016, both Intellia and Regeneron Pharmaceuticals (REGN - Free Report) initially entered into a partnership to co-develop and commercialize CRISPR/Cas-based therapies, primarily focused on genome editing in the liver. In fact, NTLA-2001 is part of a co-development and co-promotion agreement with Regeneron. While Intellia is the lead party for NTLA-2001, Regeneron will share 25% of the development costs and commercial profits.
In 2020, the collaboration between the two companies was further expanded to co-develop therapies for hemophilia A and hemophilia B, with Regeneron being the lead party.
Intellia’s collaboration with Regeneron has been encouraging. As of Sep 30, 2021, the company recorded $145.0 million in upfront payments under the collaboration.
In October 2021, Intellia partnered with SparingVision to develop novel genomic medicines utilizing the CRISPR/Cas9 technology for the treatment of ocular diseases. SparingVision will fund the preclinical and clinical development for genome editing product candidates under the collaboration. Intellia will receive a 10% equity ownership stake in SparingVision and milestone payments up to $200 million per product.
Apart from NTLA-2001, the company is evaluating another in-vivo CRISP/Cas9 candidate in hereditary angioedema (HAE). Earlier this month, Intellia initiated a phase I/II study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-2002 in adults with type I or type II HAE.
Following the initiation of the phase I/II study, NTLA-2002 became the first single-dose CRISPR/Cas9 therapy designed to prevent attacks in HAE patients to enter clinical studies. NTLA-2002 aims to prevent HAE attacks by suppressing the plasma kallikrein activity. A reduction in kallikrein activity has been clinically validated in preventing HAE attacks.
NTLA-5001 is the company’s first wholly-owned ex-vivo genome editing candidate for the treatment of cancer. Intellia intends to start clinical studies for NTLA-5001 in acute myeloidleukemia.
A handful of other companies are also evaluating and/or developing their own in-vivo and ex-vivo therapies related to Intellia’s research and development programs.
One such company is CRISPR Therapeutics (CRSP - Free Report) , which is also developing therapies using the CRISPR/Cas9 technology.
CRISPR Therapeutics is evaluating its lead candidate, CTX001, in a phase I/II study for treating transfusion-dependent beta thalassemia and sickle cell disease. It expects regulatory submission for the therapy with the FDA in both indications by 2022-end.
Apart from CTX001, CRISPR Therapeutics is also pursuing the development of CRISPR candidates to create next generation CAR-T cell therapies.
Intellia Therapeutics, Inc. Price
Intellia Therapeutics, Inc. price | Intellia Therapeutics, Inc. Quote
Zacks Rank & Stock to Consider
Intellia currently carries a Zacks Rank #3 (Hold). A better-ranked company in the same sector is Precision BioSciences (DTIL - Free Report) , which currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Precision BioSciences’ loss per share estimates for 2021 have narrowed from $1.17 to $0.65 in the past 60 days. The same for 2022 has narrowed from $2.39 to $1.91 in the past 60 days.
Earnings of Precision BioSciences beat estimates in all the last four quarters, delivering a surprise of 76.9%, on average.